MCHP's liquidation posture is deeply negative at December 31, 2025, consistent with the MFFAIS-reported CLV of approximately -$6.2B. The balance sheet carries $14.3B in total assets against a liability stack that, at face value, consumes all recoverable asset value and then some. Applying standard liquidation haircuts illustrates the deficit: cash of $251M recovers at 100% ($251M); net AR of $731M recovers at ~90-95% (~$660-695M); inventory of $1.06B recovers at ~60% (~$635M); net PP&E of $1.13B recovers at 50-70% ($565M-$791M); and goodwill of $6.70B plus net intangibles of $2.10B recover at 0%. Total recoverable asset value under liquidation is roughly $2.1B-$2.4B. Against this, total liabilities at face value include $5.39B principal debt (long-term, all fixed rate), $1.06B current liabilities, $572M non-current accrued income taxes, $738M other non-current liabilities, and a $1.49B Series A Preferred Stock liquidation preference that ranks ahead of common equity. The liability stack well exceeds recoverable asset value, producing a deeply negative recovery for common equity holders. The Series A Preferred, with a $1,000/share liquidation preference totaling $1.485B in stated preference value, absorbs what residual value might exist after debt settlement, leaving common equity with no recovery. Since the prior filing (September 30, 2025, debt at $5.41B), gross debt decreased marginally by ~$17M to $5.39B, driven by $1.2B repayment of the 4.25% 2025 Notes partially offset by net Commercial Paper issuance that grew CP outstanding from $1.12B to $1.11B. Cash declined $521M over the nine-month period, primarily consumed by $818M in dividends (common and preferred combined), financing activities, and net debt repayment. Goodwill of $6.70B and net intangibles of $2.10B together represent ~61% of reported total assets and zero recovery value under liquidation, structurally anchoring the negative equity recovery. Off-balance-sheet tax contingencies—Malaysia IRB ($410M potential liability) and German GTA ($92M)—are not on the balance sheet but represent additional face-value exposure if adjudicated adversely, worsening the recovery posture further.
▼ Community Notes